Objective:

To quantitatively synthesize evidence on the association between elevated serum M2BPGi and hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) and C (HCV).

Approach:

• Search Strategy: Conducted a systematic search across multiple databases for longitudinal studies reporting hazard ratios (HRs) for HCC linked to elevated M2BPGi in CHB or HCV.
• Data Analysis: Performed random-effects meta-analysis with restricted maximum likelihood and Hartung–Knapp adjustment on eligible studies.

Key Findings:

• Twenyhrpublicaos24dmg1689vf5307

Interpretation:

Elevated serum M2BPGi is strongly associated with HCC development in patients with chronic hepatitis B and C, with implications for risk stratification in surveillance.

Limitations:

• Egrstindcapolubhfmy35kvwxz

Conclusion:

M2BPGi is a credible candidate for enhancing current viral hepatitis surveillance, particularly for risk stratification after virological control.

Sources:

• Systematic Review Registration